Why Biogen Stock Sank While the Market Soared on Thursday

Bullishness was in the air on the stock market on Tuesday, but you’d hardly know that from the performance of Biogen (NASDAQ: BIIB). The healthcare sector mainstay saw its share price slump by over 2% that trading session, in contrast to the gravity-defying S&P 500 index’s nearly 3% increase. Investors were clearly unimpressed with the company’s latest acquisition news.

Biogen announced prior to market open that it has agreed to acquire a peer, Apellis Pharmaceuticals (NASDAQ: APLS). The agreed price is $41 per share, payable in cash, valuing the deal’s total at roughly $5.6 billion. Apellis investors will also receive a non-transferable contingent value right for each share they hold; this will entitle them to receive two payments of $2 per share if Apellis’s star Syfovre drug meets certain sales benchmarks.

Will AI create the world’s first trillionaire? Our team just released a report on the one little-known company, called an “Indispensable Monopoly” providing the critical technology Nvidia and Intel both need. Continue »

Image source: Getty Images.

Apellis currently has two Food and Drug Administration (FDA)-approved treatments on the U.S. market. In addition to Syfovre, which targets geographic atrophy (GA) secondary to age-related macular degeneration (AMD; an eye disorder), it also has Empaveli.

This drug, which like Syfovre is based on the active ingredient of pegcetacoplan, is FDA-approved for three rare afflictions, blood disease paroxysmal nocturnal hemoglobinuria (PNH) and kidney disorders C3 glomerulopathy (C3G) and primary IC-MPGN.

As with many deals in the pharmaceutical world, this one is driven by those two successful drugs. Biogen quoted CEO Christopher Viehbacher as saying that “The addition of Apellis expands our growth portfolio in immunology and rare disease with two approved, best-in-class medicines that complement our existing portfolio and bolster our near-and long-term growth potential.”

Biogen is a company in transformation, shifting from its previous strength in the multiple sclerosis market to growth products in therapeutic areas such as Alzheimer’s and postpartum depression. Yes, $5.6 billion is a large chunk of change, but it shows Biogen’s commitment to its pivot, and the two products it’s getting are valuable. I’d be less bearish on its future than many investors were on Tuesday.

Before you buy stock in Biogen, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Biogen wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Netflix made this list on December 17, 2004… if you invested $1,000 at the time of our recommendation, you’d have $501,381!* Or when Nvidia made this list on April 15, 2005… if you invested $1,000 at the time of our recommendation, you’d have $1,012,581!*

Now, it’s worth noting Stock Advisor’s total average return is 880% — a market-crushing outperformance compared to 178% for the S&P 500. Don’t miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.

See the 10 stocks »

*Stock Advisor returns as of March 31, 2026.

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool recommends Biogen. The Motley Fool has a disclosure policy.

Why Biogen Stock Sank While the Market Soared on Thursday was originally published by The Motley Fool

Source link

Visited 1 times, 1 visit(s) today

Related Article

Why AlTi Global Stock Lagged the Market Today

AlTi Global (ALTI +0.83%) stock inched up on Tuesday, but given how frothy the market was that day, it could have done better. Investors traded the wealth and asset management company’s shares up by 0.6%, which was easily topped by the benchmark S&P 500 index’s robust 2.9% gain. The main reasons for this were the

Stock Market Today, March 31: Bitmine Immersion Technologies Jumps on Crypto Recovery Hopes

Bitmine Immersion Technologies Today’s Change (8.09%) $1.48 Current Price $19.78 Key Data Points Market Cap $8.3B Day’s Range $18.36 – $19.98 52wk Range $3.20 – $161.00 Volume 70M Avg Vol 45M Gross Margin 93.80% Dividend Yield 0.05% Bitmine Immersion Technologies (BMNR +8.09%), a digital asset mining and Ethereum (ETH +3.14%)  treasury company, closed Tuesday at

Top ASX Dividend Stocks To Watch In March 2026

As the Australian market navigates a cautious start to March, with eyes on decisions from the Reserve Bank and Fair Work that could sway investor sentiment, attention turns to dividend stocks as a potential source of stability amid economic uncertainties. In this environment, selecting strong dividend-paying stocks can offer investors steady income streams and resilience

Why Savvy Investors Are Loading Up on These 2 Stocks Amid Market Chaos

Will AI create the world’s first trillionaire? Our team just released a report on the one little-known company, called an “Indispensable Monopoly” providing the critical technology Nvidia and Intel both need. Continue » People become rich by strategically building positions during market downturns. The Strait of Hormuz blockade has caused crude oil futures to surge by almost

Stocks explode as the US-Iran war may come to an end: Daily US Stock Market outlook and a step back on recent developments

Elior Manier Market Analyst Elior brings over seven years of experience in financial markets to our analyst team. Since 2018, he has actively engaged in observing, charting, and trading, driven by his passion for mastering market dynamics. With a profound understanding of the geopolitical and macroeconomic forces that shape market movements, Elior focuses on analysing

The Best Dividend Stocks to Buy and Hold Forever

Stock market investing can be stressful. After all, it’s no fun to see your net worth fluctuate up and down like a roller coaster. That said, investors who want to sleep a little easier should consider betting on stable blue chip companies with large dividends. These businesses tend to experience less volatility, and the combination

3 Tech Stocks the Market Sold Off for the Wrong Reasons This Past Month

There are several top tech stocks down over the past month for the wrong reasons, and now could be a great time to scoop up shares. Let’s look at three top artificial intelligence (AI) stocks to buy now, while their shares are down. Nvidia (NASDAQ: NVDA) shares are down about 7.5% over the past month

Is Microsoft Stock a Value Trap?

The definition of a value trap: A highly regarded stock that tumbles, that may look like an obvious buy, but is actually declining due to genuine problems within the business. Most investors regard Microsoft (MSFT +1.76%) as a world-class company. Its tech empire is far-reaching, and the company is deeply involved in the growing market

Which $1,000 Investment Wins by the End of 2026?

The investment world is currently split between the safe bet of AI and the high ceiling of crypto. Nvidia (NVDA) remains the most talked-about stock on the planet, while XRP (XRP-USD) is fighting for a major comeback. If you put $1,000 into either today, the difference in where that money ends up by December 2026

US Stock Market Today S&P 500 Futures Rise As Energy And Rate Jitters Persist

The Morning Bull – US Market Morning Update Tuesday, Mar, 31 2026 US stock futures are pointing higher this morning, with E-mini S&P 500 and Nasdaq-100 contracts up around 0.8%, as investors balance relief over interest rates with fresh worries about energy costs. The US 10 year Treasury yield sits near 4.32% after comments from

Hang Seng Indexes Company and Korea Exchange Launch the First Co-branded HK-Korea Cross-Market Index Series to Deepen Capital Market Connectivity

HONG KONG, March 31, 2026 /PRNewswire/ — Hang Seng Indexes Company (‘HSIL’) and Korea Exchange (‘KRX’) today jointly announced the launch of the Hang Seng KRX HK-Korea Index Series, marking the first co-branded cross-market index collaboration between the two organisations and a significant step in deepening capital market connectivity between Hong Kong and Korea. By

1 Magnificent Growth Stock Down 32% That Smart Money Is Quietly Accumulating

Increased market turmoil is hitting the Magnificent Seven, with Microsoft (MSFT +0.63%) taking the hardest hit out of all of them. It has fallen 33.5% from its 52-week high. A general sell-off in artificial intelligence (AI) stocks impacted the company amid massive capital expenditures (capex) spending. Investors also harbor doubts about its partnership with OpenAI.

The Dow Jones Industrial Average Is in Correction Territory: 2 Historically Cheap Components That Make for No-Brainer Buys Right Now

Volatility has returned to Wall Street. As of the closing bell on March 27, the stock market’s most iconic index, the Dow Jones Industrial Average (^DJI +0.11%), has officially entered correction territory (down 10.01% from its all-time closing high). While the benchmark S&P 500 (^GSPC 0.39%) hasn’t reached correction territory, the Dow is being kept

Middle Eastern Penny Stocks To Watch In March 2026

Amid escalating tensions in the Middle East, regional stock markets have experienced a retreat, with most Gulf indices slipping due to geopolitical uncertainties. However, Saudi Arabia’s market has shown resilience, edging higher despite the broader regional downturn. In such volatile times, penny stocks—often smaller or newer companies—can still present valuable investment opportunities when backed by

Worried About a Stock Market Crash? History Says Don’t Sweat It.

So far in 2026, the S&P 500 index (^GSPC 0.39%) is down roughly 7%, but the ride has felt much worse, as a series of events has hampered market returns. Whether it’s the Iran war and the volatile oil prices that followed, persistent tariff and inflation concerns, a weakened consumer in a K-shaped recovery, or

Decent Holding launches AI senior care arm in China

Weekly progress on share repurchase program to cover share plans and reduce capital

Press Release Weekly progress on share repurchase program to cover share plans and reduce capital Kaiseraugst (Switzerland), Maastricht (Netherlands), March 31, 2026 dsm-firmenich, innovators in nutrition, health, and beauty, announced on February 9, 2026 its intention to repurchase ordinary shares with an aggregate market value of €500 million and reduce its issued capital. On March

3 Asian Stocks Estimated To Be Trading At Up To 37.5% Below Intrinsic Value

As geopolitical tensions and energy price volatility continue to influence global markets, Asian equities have not been immune to these pressures. Despite these challenges, opportunities may exist for investors seeking undervalued stocks that are trading below their intrinsic value. In such a climate, identifying stocks with strong fundamentals and potential for growth can be key

0
Would love your thoughts, please comment.x
()
x